Immune modulation attenuates infantile neuronal ceroid lipofuscinosis in mice before and after disease onset. Issue 2 (21st March 2021)

• Record Type: Journal Article
• Authors: Groh, Janos; Berve, Kristina; Martini, Rudolf
• Is Part Of: Brain communications. Volume 3:Issue 2(2021)
• Publication Date: 2021-03-21
• Subjects: infantile neuronal ceroid lipofuscinosis -- neuroinflammation -- immunomodulation -- T-lymphocytes -- neurodegeneration -- attenuation of disease -- preventive treatment; 616
• DOI: 10.1093/braincomms/fcab047
• Languages: English
• ISSNs: 2632-1297

Abstract

Abstract: Targeting neuroinflammation in models for infantile and juvenile forms of neuronal ceroid lipofuscinosis (NCL, CLN disease) with the clinically established immunomodulators fingolimod and teriflunomide significantly attenuates the neurodegenerative phenotype when applied preventively, i.e. before the development of substantial neural damage and clinical symptoms. Here, we show that in a mouse model for the early onset and rapidly progressing CLN1 form, more complex clinical phenotypes like disturbed motor coordination and impaired visual acuity are also ameliorated by immunomodulation. Moreover, we show that the disease outcome can be attenuated even when fingolimod and teriflunomide treatment starts after disease onset, i.e. when neurodegeneration is ongoing and clinical symptoms are detectable. In detail, treatment with either drug led to a reduction in T-cell numbers and microgliosis in the CNS, although not to the same extent as upon preventive treatment. Pharmacological immunomodulation was accompanied by a reduction of axonal damage, neuron loss and astrogliosis in the retinotectal system and by reduced brain atrophy. Accordingly, the frequency of myoclonic jerks and disturbed motor coordination were attenuated. Overall, disease alleviation was remarkably substantial upon therapeutic treatment with both drugs, although less robust than upon preventive treatment. To test the relevance of putative immune-independent mechanisms of action in this model, we treated CLN1 mice lacking mature T- and B-lymphocytes. Immunodeficient CLN1 mice showed, as previously reported, an improved neurological phenotype in comparison with genuine CLN1 mice which could not be further alleviated by either of the drugs, reflecting a predominantly immune-related therapeutic mechanism of action. The present study supports and strengthens our previous view that repurposing clinically approved immunomodulators may alleviate the course of CLN1 disease in human patients, even though diagnosis usually occurs when symptoms have already emerged. Abstract : In models of neuronal ceroid lipofuscinoses, preventively targeting neuroinflammation attenuates neurodegeneration. Here Groh et al. show that in a model for infantile neuronal ceroid lipofuscinosis also complex clinical phenotypes like visual acuity, can be ameliorated by immunomodulation. Importantly, treatment after disease onset also mitigates disease, albeit less robustly than preventive treatment. Graphical Abstract: